Daniel Lee is an Oncology physician. ClinicalTrials.gov lists 6 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
281 Lincoln St
Medical Staff Svcs
Worcester, MA 016052138
Telephone
508-334-1131Provider last certified this registry record 13 Jul 2022.
Clinical trials
- Distribution of Medication Disposal Packets - Acute Opioid Prescribing
Sponsor: University of Pennsylvania
- FITBIT Study on Mobility and Readmissions After Radical Cystectomy
Sponsor: University of Pennsylvania
- IOP and Medication Reduction in MIGS Procedures
Sponsor: Wills Eye
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
1 company reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Shockwave Medical, IncProgram year202510 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2020)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Metabolism & gastrointestinal
60.7%Corticosteroid60.7%Prednisone100%Part D<11 patientsCancer & immunology
39.3%Cytochrome P450 17A1 Inhibitor39.3%Abiraterone Acetate100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
2 NIH research awards on record, funded 2003–2013 per NIH RePORTER. The latest:
- Delivery of Channel Rhodopsin for Optogenetic Control of Neurons in the Cochlea
Massachusetts Eye and Ear Infirmary
FY2013$194,157R21DC012422 - Delivery of Channel Rhodopsin for Optogenetic Control of Neurons in the Cochlea
Massachusetts Eye and Ear Infirmary
FY2012$242,250R21DC012422 - Central auditory pathway of the middle ear reflex
Univ of Massachusetts Med Sch Worcester
FY2007$190,844K08DC006285
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Similar KOLs
Other experts from the same institution or the same specialty.
Freddie Bray
Centre National de la Recherche Scientifique
Jacques Ferlay
Centre international de recherche sur le cancer
Hermann Brenner
German Cancer Research Center
Isabelle Soerjomataram
Centre international de recherche sur le cancer
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”